...August 30, 2022 TOKYO (S&P Global Ratings) Aug. 30, 2022--Olympus Corp. has boosted its capacity for growth investment through the sale of its scientific solutions business. We think this could eventually boost the business competitiveness of the Japan-based medical technology company. On Aug. 29, 2022, the company announced that it will transfer its scientific solutions business, which includes industrial microscopes, to U.S.-based Bain Capital Private Equity LP for Ñ427.6 billion. We think if Olympus (###+/Stable/--) uses the proceeds from the sale of the scientific solutions business to spend mainly in the therapeutic solutions area, it will likely enhance the company's business competitiveness over the medium term. The company has retained a large market share and strong profitability in its mainstay endoscope business. However, it lags competitors at home and abroad in terms of size and profitability in the therapeutic solutions business. We therefore expect the company to make more...
